Patent directory · USPTO A61K / A61P
Patents matching “adenosine”
64 pharma patents match "adenosine" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 64 pharmaceutical patents matching "adenosine" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 7189706
C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them
granted -
US 7141434
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinase
granted -
US 7112574
C2,8-disubstituted adenosine derivatives and their different uses
granted -
US 7084127
C2,5′-disubstituted and N6, C2,5′-trisubstituted adenosine derivatives and their different uses
granted -
US 7064112
Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
granted -
US 6911435
Method of treating leukopenia with adenosine
expired -
US 6790839
Pharmaceutical administration of adenosine agonists
expired -
US 6638914
Pharmaceutical administration of adenosine agonists
expired -
US 6620825
Adenosine A3 receptor antagonists
expired -
US 6586413
Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
expired -
US 6579857
Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
expired -
US 6436966
Adenosine A3 receptor antagonists
expired -
US 6329349
Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents
expired -
US 6214571
Method for inhibiting adenylosuccinate synthetase activity in malignant methylthioadenosine phosphorylase deficient cells
expired -
US 6211165
Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
expired -
US 6066642
Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
expired